Total hip arthroplasty (THA) has been shown to reduce pain and improve function. In addition, it is suggested that THA improves sleep and alleviates symptoms of anxiety and depression. Patients with chronic pain are frequent users of analgesic and psychotropic drugs and thereby risk adverse drug events. The impact of THA on such drug use has not been thoroughly investigated. Based on merged data from the Norwegian Prescription Database and the Norwegian Arthroplasty Register, this study sought to investigate redeemed medications in a complete population (N = 39,688) undergoing THA in 2005 to 2011. User rates and redeemed drug volume of analgesics (nonsteroid anti-inflammatory drugs (NSAIDs), opioids, and nonopioids) and psychotropics (hypnotics, anxiolytics, and antidepressants) were calculated for 4 quarters before and 4 quarters after surgery. We analysed preoperative prescription trends (Q1 vs Q4), postoperative prescription (Q4 vs Q5), and long-term effect of surgery (Q4 vs Q8). Before surgery, use of all drug groups increased from Q1 to Q4. Use of opioids, nonopioids, and hypnotics dramatically increased from Q4 to Q5. Long-term (Q4 vs Q8) surgery reduced prescriptions of analgesics, hypnotics, and anxiolytics, but not antidepressants. Overall, the present results extend the positive effects of THA to include reduced reliance on medication to alleviate symptoms.
Total Hip Arthroplasty reduces prescription use of analgesics, hypnotics, and anxiolytics and prescription trajectories follow clinical pain trajectories for analgesics and hypnotics before and after surgery.
aDepartment of Clinical Psychology, University of Bergen, Bergen, Norway
bDepartment of Behavioural Sciences in Medicine, University of Oslo, Oslo, Norway
cDepartment of Biological and Medical Psychology, University of Bergen, Bergen, Norway
dSleep and Performance Research Center, College of Medical Sciences, Washington State University, Spokane, WA, USA
eDepartment of Clinical Medicine, University of Bergen, Bergen, Norway
fDepartment of Orthopaedics, Haukeland University Hospital, Bergen, Norway
gDepartment of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
hResearch Unit for General Practice, Uni Research Health, Bergen, Norway
iKavli Research Center for Ageing and Dementia, Haraldsplass Hospital, Bergen, Norway
jDepartment of Clinical Science, University of Bergen, Bergen, Norway
kDiakonhjemmet Hospital, Oslo, Norway
lThe Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, Bergen, Norway
mDepartment of Psychosocial Science, University of Bergen, Bergen, Norway
Corresponding author. Address: Department of Clinical Psychology, University of Bergen, PO Box 7807, 5015 Bergen, Norway. Tel.: +4792218442; fax: 47 55 58 98 77. E-mail address: firstname.lastname@example.org (T. Blågestad).
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Received June 26, 2015
Received in revised form August 17, 2015
Accepted September 01, 2015